Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human papillomavirus type 11 L1 major capsid protein is the primary structural component of the HPV11 viral capsid, which self-assembles into pentameric capsomeres and further into icosahedral virus-like particles (VLPs). HPV11 is a low-risk mucosal human papillomavirus responsible for approximately 90% of genital warts (condyloma acuminata) and recurrent respiratory papillomatosis. The L1 protein contains highly immunogenic, conformationally dependent epitopes located on its surface-exposed hypervariable loops. These conformational epitopes are the primary targets for neutralizing antibodies that block viral attachment to host cell heparan sulfate proteoglycans and subsequent internalization.
Prophylactic vaccines, such as the quadrivalent Gardasil and nonavalent Gardasil 9, utilize recombinant HPV11 L1 VLPs to elicit robust, type-specific neutralizing antibody responses that prevent initial infection. Because these vaccines are composed of empty capsids lacking viral DNA, they are non-infectious and non-oncogenic. Efficacy and immunogenicity are typically monitored by measuring serum anti-HPV11 L1 IgG and neutralizing antibody titers. While highly effective at preventing infection, these L1-targeted vaccines do not possess therapeutic efficacy against pre-existing HPV11 infections or lesions.
Active immunization to induce type-specific neutralizing antibodies that block viral attachment and entry into host cells
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus type 11 L1 major capsid protein (HPV11 L1).